Pancreatic cancer is fast becoming a global menace and it is projected to be the second
leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which …

This review summarizes recent development in synthetic drugs and biologics targeting
intracellular driver genes in epithelial cancers, focusing on KRAS, and provides a current …

Pancreatic Ductal Adenocarcinoma (PDAC) is projected to become the 2nd leading cause of
cancer-related deaths in the United States. Limitations in early detection and treatment …

Simple Summary Pancreatic cancer is difficult to treat. Novel treatment strategies are
urgently needed to improve the survival rate, which is approximately 10% five years after …

Antibodies conjugated with diagnostic/therapeutic radionuclides are attractive options for
inoperable cancers lacking accurate imaging methods and effective therapeutics, such as …

Simple Summary Pancreatic cancer is an insidious disease, often diagnosed late in its
course when curative treatments are moot, with a 5-year median overall survival of~ 12 …

Background Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with
an unmet clinical demand. Development of radioimmunoconjugates which target cancer …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of
cancer deaths in the United States due to its late-stage diagnosis. Currently, there are no …

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most lethal cancers
to date, with a 5-year survival rate of only 12%. The poor survival rate can largely be …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and chemotherapeutic
resistant disease, which is virtually incurable with current treatment modalities. Unlike other …